Mark J. Bamberger
Plus aucun poste en cours
Profil
Mark J.
Bamberger worked as the Director of Cardiovascular Disease Research at Pfizer Inc. from 2004 to 2008.
He also served as the Chief Scientific Officer at Stealth BioTherapeutics Corp.
from 2014 to 2020.
Bamberger received his undergraduate degree from St. Joseph's University in 1974 and his doctorate from Drexel University College of Medicine.
Anciens postes connus de Mark J. Bamberger
| Sociétés | Poste | Fin |
|---|---|---|
| STEALTH BIOTHERAPEUTICS CORP | Chief Tech/Sci/R&D Officer | 01/01/2020 |
| PFIZER, INC. | Corporate Officer/Principal | 01/01/2008 |
Formation de Mark J. Bamberger
| St. Joseph's University | Undergraduate Degree |
| Drexel University College of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PFIZER, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Stealth BioTherapeutics Corp.
 Stealth BioTherapeutics Corp. BiotechnologyHealth Technology Stealth BioTherapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. The company was founded on April 3, 2006 and is headquartered in Needham, MA. | Health Technology |
